Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33185
Title: Implementation of Partnered Pharmacist Medication Charting in haematology and oncology inpatients.
Austin Authors: Tong, Erica Y;Edwards, Gail E;Hua, Phuong Uyen;Mitra, Biswadev;Dyk, Eleanor Van;Yip, Gary;Coutsouvelis, John;Siderov, Jim ;Tran, Yen;Dooley, Michael J
Affiliation: Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia.
Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Pharmacy
Department of Oncology, Epworth Healthcare, Richmond, Victoria, Australia.
Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia.
;Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Issue Date: 23-Jun-2023
Date: 2023
Publication information: Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners2023-06-23
Abstract: Partnered Pharmacist Medication Charting (PPMC) in patients admitted under general medical units has been shown to reduce medication errors. The aim of this study is to evaluate the impact of the PPMC model on medication errors in patients admitted under cancer units in Victorian hospitals. A prospective cohort study comparing cohorts before and after the introduction of PPMC was conducted. This included a 2-month pre-intervention phase and 3-month intervention phase. PPMC was implemented during the intervention phase as new model of care that enabled credentialed pharmacists to chart all admission medications, including pre-admission or new medications and cancer therapies, in collaboration with the admitting medical officer. The proportion of medication charts with at least one error was the primary outcome measure. Seven health services across Victoria were included in the study. The majority of health services were using paper-based prescribing systems for oncology. Of the 547 patients who received standard medical medication charting, 331 (60.5%) had at least one medication error identified compared to 18 out of 416 patients (4.3%) using the PPMC model (p < 0.001). The median (interquartile range) inpatient length of stay was 5 (2.9-10.6) days in pre-intervention and 4.9 (2.9-11) days in intervention (p  =  0.88). In the intervention arm, 42 patients had cancer therapy charted by a pharmacist with no errors. PPMC was successfully scaled into cancer units as a collaborative medication safety strategy. The model was associated with significantly lower rates of medication errors, including cancer therapies. PPMC should be adopted more widely in cancer units in Australia.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33185
DOI: 10.1177/10781552231180468
ORCID: 0000-0002-1638-004X
Journal: Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Start page: 10781552231180468
PubMed URL: 37350675
ISSN: 1477-092X
Type: Journal Article
Subjects: Medication error
cancer services
inpatient
prescribing
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on Nov 7, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.